| Not Yet Recruiting | FXS6837 for the Treatment of IgAN Patients IgAN | Phase 2 | 2026-03-31 |
| Not Yet Recruiting | Phase I Study of FXS887 in the Treatment of Solid Tumors Solid Tumor Refractory to Conventional Treatment | Phase 1 | 2026-01-05 |
| Not Yet Recruiting | FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With B Low-grade Glioma, Pediatric Low-grade Gliomas, pLGG With BRAF Alteration | Phase 3 | 2025-06-30 |
| Not Yet Recruiting | Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosi Neurofibromatosis 1, Plexiform Neurofibroma, NF1 | Phase 1 / Phase 2 | 2025-06-12 |
| Recruiting | To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recu Langerhans Cell Histiocytosis, LCH | Phase 2 | 2023-09-28 |
| Active Not Recruiting | FCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid Neoplasms Safety, Antitumor Activity, PK Profile | Phase 2 | 2023-08-16 |
| Active Not Recruiting | FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibroma Neurofibromatosis 1, Plexiform Neurofibroma, NF1 | Phase 3 | 2023-06-20 |
| Unknown | FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Breast Cancer | Phase 3 | 2023-03-28 |
| Active Not Recruiting | Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC Non-Small Cell Lung Cancer, ALK-positive, SAF-189s | Phase 3 | 2021-12-31 |
| Active Not Recruiting | Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Neurofibromatosis 1, Plexiform Neurofibroma, NF1 | Phase 1 / Phase 2 | 2021-03-26 |
| Completed | Phase 1 Study of FS-1502 in Patients With HER2 Expressed Advanced Solid Tumors and Breast Cancer. Solid Tumor, Breast Cancer | Phase 1 | 2019-10-11 |
| Suspended | MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b) Melanoma | Phase 1 | 2019-03-21 |
| Terminated | A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML Advanced Cancer, Solid Tumors, Acute Myeloid Leukemia Refractory | Phase 1 | 2018-07-23 |
| Unknown | A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients Advanced Cancer, Advanced Solid Tumor, Lung Cancer, Nonsmall Cell | Phase 1 / Phase 2 | 2016-11-14 |